

Practitioner's Docket No. MPI98-148P1USRCE2M

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Phillips, David R., et al.

Application No.:

09/673,302

Group No.:

1632

Filed:

March 23, 2001

Examiner:

Ton, Thaian N.

For:

TRANSGENIC MICE EXPRESSING MUTANT GP IIIA (β3) PROTEIN

Mail Stop RCE Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

SUBMISSION OF "SEQUENCE LISTING," COMPUTER READABLE COPY, AND/OR AMENDMENT PERTAINING THERETO FOR BIOTECHNOLOGY INVENTION CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE

1. ((x) This replies to the Office communication dated July 12, 2004.					
	() A copy of the Office communicat	tion is enclosed	· .			
	IDENTIFICATION OF P	ERSON MAK	ING STATEMENT			
2. I	, Tracy M. Sioussat					
	(type or print nam	e of person sig	ning below)			
·						
	CERTIFICATION UNDER	37 C.F.R. SECT	IONS 1.8(a) and 1.10*			
I here	by certify that, on the date shown below, this correspo	ondence is being:				
	,	MAILING				
×	deposited with the United States Postal Service in an envelope addressed to Mail Stop RCE, Commissioner for Patents P. O. Box 1450, Alexandria, VA 22313-1450.					
	37 C.F.R. SECTION 1.8(a)		37 C.F.R. SECTION 1.10*			
	with sufficient postage as first class mail.	Ø	as "Express Mail Post Office to Address" Mailing Label No. <u>EV512402416US</u>			
_		NSMISSION	1			
transmitted by facsimile to the Patent and Trademark Office: Swelly Satisfy						
		Signatu	ire /			
Date: July 23, 2004		Bever	Beverly Sotiropoulos			
		(type or	print name of person certifying)			

*WARNING:Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

(Submission-Nucleotide and/or Amino Acid Sequence-page 1 of 3)

Practitioner's Docket No. MPI98-148P1USRCE2M

ITEMS BEING SUBMITTED

		,					
3.	Submitted herew	vith are:					
	A. [x] "Sequence Listing(s)" for the nucleotide and/or amino acid sequence(s) in this application (5 pages). Each "Sequence Listing" is assigned a separate identifier as required in 37 C.F.R. Section 1.821(c) and 37 C.F.R. Sections 1.822 and 1.823.						
	B. () An amendment to the description and/or claims, wherein reference is made to the sequence by use of the assigned identifier, as required in 37 C.F.R. Section 1.821(d).						
C. [x] A copy of each "Sequence Listing" submitted for this application in computer reaccordance with the requirements of 37 C.F.R. Sections 1.821(e) and 1.824.							
		ransfer to this application, in acc lable copy(ies) from applicant's o		.R. Section 1.821(e), the computer tified as follows:			
In 1	re application of:						
	plication No.:		Group No.:	•			
File	ed:		Examiner:				
For							
	•	application as follows:	t's other application	corresponds to the "Sequence			
			Sequence identifier				
(0	other application)	,		(this application)			
 .		,					
	readable	e copy are the same, as required	in 37 C.F.R. Section by a person register	red to practice before the Office,			
	• •	this submission is made in), a statement that the submissio		rement under 37 C.F.R. Section natter.			

Practitioner's Docket No. MPI98-148P1USRCE2M

[] Because the statement is not made by a person registered to practice before the Office, the statement is verified, as required in 37 C.F.R. Section 1.821(g).

STATEMENT THAT "SEQUENCE LISTING" AND COMPUTER READABLE COPY ARE THE SAME AND/OR THAT PAPERS SUBMITTED INCLUDES NO NEW MATTER

- 4. I hereby state:
 - A. [x] Each computer readable form submitted in this application, including those forms requested to be transferred from applicant's other application, is the same as the "Sequence Listing" to which it is indicated to relate.
 - B. (x) All papers accompanying this submission, or for which a request for transfer from applicants' other application, introduce no new matter.

FEE DEFICIENCY

5. (x) If any additional extension and/or fee is required, charge Account No. 501668.

July 23, 2004

MILLENNIUM PHARMACEUTICALS, INC.

Sv ,

Trady M. Sioussat, Ph.D. Registration No. 50,609 40 Landsdowne Street Cambridge, MA 02139

Telephone – (617) 374-7679

Facsimile - (617) 551-8820